News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Photo of Tom Powles taken from bartscancer.london
Apr 11, 2024, 08:13

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“Trial in progress: The HER2/MMAE Antibody Drug Conjugates, Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma (HER2+ve). DVs efficacy looks increased also with Immuno-oncology (IO). Toxic profile looks distinct with? Decreased skin toxicity? EAU24 results will be considered in the context of other positives first line studies.”

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Source: Tom Powles/X

Antibody drug conjugates Avelumab Barts Cancer Center cancer chemotherapy Disitimab EAU24 HER2 Immuno-oncology (IO) OncoDaily Oncology pembrolizumab Skin Toxicity Tom Powles Toxic profile Trial Vedotin
Special Coverage
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology
Insight
Nov 13, 2024, 09:27
Nikki Rossetti et al. on Early-Stage Lung Cancer in the Era of Lung Cancer Screening
Blog
Nov 13, 2024, 09:14
Yüksel Ürün: Key takeaways on high-risk and locally advanced prostate cancer from António Rui Azevedo Freitas
Blog
Nov 13, 2024, 09:11
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy
Blog
Nov 13, 2024, 09:09
Yüksel Ürün: Not all that shines is Prostate cancer – a striking reminder from Daniela Oprea-Lager
Blog
Nov 13, 2024, 09:01
Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer
Blog
Nov 13, 2024, 08:59
Miriam Mutebi: What To Expect During A Mammogram
Insight
Nov 13, 2024, 08:56
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Insight
Nov 13, 2024, 08:51
Reporting pharmacogenetic variants and cancer WGS data could guide safer prescribing
Blog
Nov 13, 2024, 08:49
Yüksel Ürün: Promising findings on SGLT2 as a biomarker for papillary RCC by Erman Akkus
Blog
Nov 13, 2024, 08:46
Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer
Blog
Nov 13, 2024, 08:39
Eva Blondeaux on safety of pregnancy in BRCA carriers